Market Cap (In SEK)
72.27 Million
Revenue (In SEK)
7.29 Million
Net Income (In SEK)
-124.82 Million
Avg. Volume
257.72 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.494-3.4
- PE
- -0.66
- EPS
- -1.22
- Beta Value
- 1.424
- ISIN
- SE0008613731
- CUSIP
- -
- CIK
- -
- Shares
- 90344991.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Anders Rylander
- Employee Count
- -
- Website
- https://www.biovica.com
- Ipo Date
- 2017-03-29
- Details
- Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
More Stocks
-
EDRWY
-
GBK
-
0425Minth Group Limited
0425
-
ALNSENSE S.A.
ALNSE
-
BEWFFBeWhere Holdings Inc.
BEWFF
-
8433Bon Fame Co., Ltd.
8433
-
PLTpoLight ASA
PLT
-
PVCT